Europe's moment: advancing clinical research and health innovation

Past event In person & online

Sustainable Livelihoods
starts
ends
Friends of Europe Europe's moment: advancing clinical research and health innovation 2025

What happened?

Clinical research sits at the heart of Europe’s health innovation and competitiveness. This was the focus of a Friends of Europe Policy Insight on 17 September 2025, gathering voices from policy, industry, investors and public-private partnerships to assess how the EU can regain momentum in trials and accelerate patient access to innovation.

Richard Robinson, Executive Director and Head of European Policy and Government Affairs at Bristol Myers Squibb (BMS), set the tone with a stark data point: “Europe’s share of global clinical trials has halved over the last decade from 18% to only 9% of global clinical research.” He argued that Europe must act as a truly harmonised market, calling for standard contractual clauses, smoother ethics procedures and cross-border patient access to speed recruitment and improve equity.

From the European Commission, Rainer Becker, Director for Medical Products and Innovation, European Commission Directorate-General for Health & Food Safety (DG SANTE), linked competitiveness with public health, noting that “when clinical trials are conducted in Europe, patients have earlier access to medicines, and launches happen more quickly.” He acknowledged slower timelines – “over 105 days… versus 40–60 days” elsewhere – and pointed to the EU Life Sciences Strategy and upcoming Biotech Act to simplify rules, reinforce coordination and promote proportionate, risk-based approaches.

Public-private partnerships emerged as practical engines for change. Nathalie Seigneuret, Senior Scientific Officer at the Innovative Health Initiative Joint Undertaking (IHI JU), highlighted concrete tools and networks – from conect4children for paediatrics to EU-PEARL platform trials and Trials@Home for decentralised models – stressing that “the idea is not only to run pilots, but to create frameworks that can be scaled up and used more widely in Europe.”

Looking ahead, Nina Rawal, Partner and Co-Head at Trill Impact Ventures and 2014 European Young Leader (EYL40), urged a shift to a European-centred model that is grounded in patient needs and payer realities. She underscored AI’s potential to cut clinical development costs and called for regulatory harmonisation and smarter, risk-based pathways: “We need to be intentional in designing a new model that is based on European patient needs and payer realities.”

Across the debate, speakers agreed that Europe can be both safe and fast: by simplifying processes, scaling PPP solutions, leveraging high-quality data and AI, and staying true to European values of patient protection. The choice, as several warned, is to seize the moment — or see Europe’s share and influence continue to erode.


Our events include photos, audio and video recording that we might use for promotional purposes. By registering you expressly confirm that you have read and understood Friends of Europe privacy policy. Should you have any questions, please contact us on privacy@friendsofeurope.org.

PHOTO CREDIT: Shutterstock | Yuliia Sihurko

Schedule

Schedule

Welcome and light lunch
Europe’s moment: advancing clinical research and health innovation
Expand Europe’s moment: advancing clinical research and health innovation
  • In what ways can the EU Life Science Strategy support new, more agile clinical research models, including decentralised and digitally enabled trials?
  • How can the EU framework support faster, more diverse and patient-focused trials?
  • What policy levers can help translate scientific excellence into faster, real-world health impact?
End of Policy Insight
Speakers

Speakers

Photo of Rainer Becker
Rainer Becker

Director for Medical Products and Innovation, European Commission Directorate-General for Health & Food Safety (DG SANTE)

Show more information on Rainer Becker

Rainer Becker is Director in the European Commission’s Directorate-General for Health and Food Safety. He heads the Directorate for Medical Products and Innovation, responsible amongst others for Europe’s Pharmaceutical Strategy and its follow-up initiatives such as the revision of pharmaceutical EU legislation and policy initiatives on availability of medicines. His directorate also leads the Commission’s policy work on medical devices and veterinary medicines. Prior to his current position, Rainer was for several years in charge of antitrust enforcement for pharmaceuticals and health in the Commission’s Directorate-General for Competition. Before joining the Commission, Rainer was a senior lawyer in an international law firm.

Nina Rawal
Nina Rawal

Partner and Co-Head at Trill Impact Ventures and 2014 European Young Leader (EYL40)

Show more information on Nina Rawal

Nina Rawal is a Partner and Co-Head at Trill Impact Ventures, Europe’s leading impact investing house. Prior to her current role, she founded Emerging Health Ventures, a venture capital fund focused on affordable medicine and medical products. She was also the head of life science at the Swedish Industrial Development Fund, a €500mn venture capital fund, where she was responsible for international business development in early life science companies. Rawal has also previously served as the head of strategy and ventures at Baxter Group, formerly Gambro, a leading global medical technology company. She also sits on the boards of MedCap AB and Stockholms Sjukhem, a non-profit hospital. In recognition of her work, Rawal has been recognised among the Women’s Forum Rising Talents.

Richard Robinson
Richard Robinson

Executive Director and Head of European Policy and Government Affairs at Bristol Myers Squibb

Show more information on Richard Robinson

Richard Robinson is the current Executive Director and Head of European Policy and Government Affairs for Bristol Myers Squibb in Europe. An experienced government affairs professional, he leads a team engaging with European Union and national policymakers to strengthen life sciences investment and expand patient access to innovative medicines. Robinson previously served as Head of Market Access and External Affairs for the United Kingdom and Ireland, ensuring patients could benefit across diverse health systems. Before joining Bristol Myers Squibb, he worked as a public affairs consultant advising healthcare organisations including the World Hepatitis Alliance, Royal Pharmaceutical Society, Pfizer and Virgin Care.

Photo of Tamsin Rose
Tamsin Rose

Facilitator

Show more information on Tamsin Rose

Tamsin Rose is a facilitator who was until recently a senior fellow for health at Friends of Europe. Having studied international relations, she has 25 years of experience working across the European continent from Ireland to Mongolia. A natural communicator, Tamsin has been a radio reporter, worked on press for the EU Delegation in Moscow and is currently a member of the external speaker team for the European Commission Directorate-General for Communication, describing how the EU works and key policies to visitor groups from around the world. Since 2002, she has specialised in public health and public participation issues, serving as the Secretary General of the European Public Health Alliance (EPHA), and providing strategic advice for health groups on how to engage successfully with the EU.

Photo of Nathalie Seigneuret
Nathalie Seigneuret

Senior Scientific Officer, Innovative Health Initiative Joint Undertaking (IHI JU)

Show more information on Nathalie Seigneuret

Nathalie Seigneuret is an experienced scientific project manager with over 25 years of expertise in the pharmaceutical regulatory and research sector. Since December 2021, she has been Senior Scientific Project Manager at the Innovative Health Initiative in Brussels, overseeing coordination and management of complex scientific projects. Prior to this, Nathalie spent over a decade at the Innovative Medicines Initiative, where she played a key role in driving collaborative health research programmes. She previously worked at the European Medicines Agency in London, focusing on centralised procedures for marketing authorisations, particularly in anti-infectives, and later specialised in paediatric development, leading the implementation of the EU Paediatric Regulation. With a strong regulatory background, Nathalie serves as a vital liaison on regulatory matters, combining scientific expertise with project leadership to advance innovative healthcare initiatives across Europe.

Partners

Activities

view all
view all
view all

Continue
the debate on

Track title

Category

00:0000:00
Stop playback
Video title

Category

Close
Africa initiative logo

Dismiss